India, July 6 -- Vertex Pharmaceuticals (VRTX) said Monday it has agreed to acquire Crinetics Pharmaceuticals (CRNX) in an all-cash deal valued at approximately $10 billion, strengthening its portfolio with commercial and late-stage endocrinology assets.
Under the agreement, Vertex will pay $85.00 per share in cash for Crinetics, representing an equity value of about $10.0 billion, or $8.8 billion net of estimated cash acquired.
The transaction has been unanimously approved by both companies' boards and is expected to close in the third quarter of 2026, subject to regulatory approvals and Crinetics shareholder approval.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The acquisition adds PALSONIFY (p...